| Identification | Back Directory | [Name]
CLORAZEPATE DIPOTASSIUM SALT | [CAS]
57109-90-7 | [Synonyms]
Azene
cb4306
4306cb
ah3232
mendon
cm4306
tr19119
latekoh
ab35616
tencilan
transene
belseren
Gen-xene
Tranzene
tranxene
tranxilen
nevracten
transilium
tranxilene
tranxilium
Nu-Clopate
chlorazepam
CLORAZEPATE
abbott-35616
chlorazepate
Novo-Clopate
Apo-Clorazepate
Clorazepate potassium
Dipotsium Clorazepate
clorazepatedipotassium
dipotassiumclorazepate
dipotassiumchlorazepate
bipotassiumchlorazepate
chlorazepatedipotassium
Chlorazepate dipotassic
QCHSEDTUUKDTIG-UHFFFAOYSA-L
Dipotassium Clorazepate API
CLORAZEPATE DIPOTASSIUM SALT
Clorazepic Acid DipotasiuM Salt
Clorazepate dipotassium solution
Clorazepic acid dipotassium salt
Clorazepate Dipotassium CIV (125 mg)
CLORAZEPATE DIPOTASSIUM--DEA SCHEDULE I&
CLORAZEPATE DIPOTASSIUM METHANOL*SOLUTIO N
Clorazepate dipotassium salt solution
monopotassiumsalt,compd.withpotassiumhydroxide
[2-Phenyl-2-(2-amino-5-chlorophenyl)-1-azavinyl]malonic acid
potassium7-chloro-2,3-dihydro-2-oxo-5-phenyl-1h-1,4-benzodiazepine-3-carboxy
7-Chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid
7-CHLORO-2,3-DIHYDRO-2,2-DIHYDROXY-5-PHENYL-1H-1,4-BENZODIAZEPINE-3-CARBOXYLIC ACID DIPOTASSIUM SALT
Clorazepate dipotassium salt,7-Chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid
Potassium (3RS)-7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H- 1,4-benzodiazepine-3-carboxylate compound with potassium hydroxide (1:1)
Potassium hydroxide, compd. with 7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid monopotassium salt (1:1)
1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (1:1)
1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, monopotassium salt, compd. with potassium hydroxide (K(OH)) (1:1)
Potassium hydroxide (K(OH)), compd. with 7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid monopotassium salt (1:1) (9CI) | [EINECS(EC#)]
260-565-6 | [Molecular Formula]
C16H13ClK2N2O4 | [MDL Number]
MFCD00063405 | [MOL File]
57109-90-7.mol | [Molecular Weight]
410.94 |
| Chemical Properties | Back Directory | [Melting point ]
228-235°C | [Fp ]
11 °C | [storage temp. ]
2-8°C | [solubility ]
Freely soluble to very soluble in water, very slightly soluble in alcohol, practically insoluble in methylene chloride. Solutions in water and in alcohol are unstable and are to be used immediately. | [form ]
Solid | [color ]
White to Pale Yellow | [Major Application]
clinical testing | [InChI]
1S/C16H12ClN2O4.2K/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-14(15(20)21)16(22,23)19-12;;/h1-8,14,19,22H,(H,20,21);;/q-1;2*+1/p-1 | [InChIKey]
UDKOZNXRMDPDLY-UHFFFAOYSA-M | [SMILES]
O=C(O[K])C1N=C(C2=CC=CC=C2)C3=C(C=CC(Cl)=C3)NC1(O)O[K] | [EPA Substance Registry System]
Clorazepate dipotassium (57109-90-7) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn,T,F | [Risk Statements ]
22-63-39/23/24/25-23/24/25-11 | [Safety Statements ]
22-36/37/39-45-36/37-16-7 | [RIDADR ]
3249 | [WGK Germany ]
3 | [RTECS ]
DE8750000 | [HazardClass ]
6.1(b) | [PackingGroup ]
III | [HS Code ]
2933910000 | [Storage Class]
3 - Flammable liquids | [Hazard Classifications]
Acute Tox. 3 Dermal
Acute Tox. 3 Inhalation
Acute Tox. 3 Oral
Flam. Liq. 2
STOT SE 1 | [Toxicity]
LD50 in mice (mg/kg): 700 orally; 290 i.p.; LD50 orally in rats: >1000 mg/kg (Brunaud) |
| Hazard Information | Back Directory | [Chemical Properties]
Pale Yellow Solid | [Originator]
Tranxene,Clin-Comar-Byla,France,1968 | [Uses]
Anxiolytic.
Controlled substance (depressant). | [Definition]
ChEBI: The compound of monopotassium clorazepate with potassium hydroxide. It is used for the management of anxiety disorders, for the short-term relief of anxiety, as adjunctive therapy in the management of epilepsy, and for the symptomatic relief of acute alcoh
l withdrawal. | [Manufacturing Process]
(A) Preparation of (2-Amino-5-Chlorophenyl)Phenylmethaneimine (4356 CB):
A solution of 228.7 g (1.5 mold of 2-amino-5-chlorobenzonitrilein 1,800 ml of
dry ether is added slowly in the course of about 3.5 hours to a solution of
phenyl magnesium bromide prepared from 109 g (4.5 g-atoms) of magnesium
turnings and 848 g (5.4 mols) of bromobenzene in 3,600 ml of anhydrous
ether, and the mixture then heated under reflux for 15 hours.
The complex is decomposed by stirring the reaction mixture into a solution
prepared from 500 g of ammonium chloride in 2,000 mi of water to which 3
kg of crushed ice have been added. After extraction and washing, the ether is
evaporated in vacuo at 40°C. The oily residue is taken up in 500 ml of
petroleum ether and left to crystallize by cooling at -20°C. The yellowish
crystals formed are dried (309 g); MPk (Kofler block): 74°C; yield: 92%.
(B) Preparation of 7-Chloro-3-Methoxycarbonyl-5-Phenyl-2-Oxo-2,3-Dihydro-
1H-Benzo[f]-1,4-Diazepine (4347 CB): A solution of 9.2 g (0.04 mol) of
compound 4356 CB in 20 ml of methanol is added dropwise, in the course of
one hour and 30 minutes, to a boiling solution of 9.2 g (0.05 mol) of the
hydrochloride of methyl aminomalonate in 30 ml of methanol. When this is
completed, heating under reflux is continued for 30 minutes and the product
then concentrated to dryness under reduced pressure. The residue is taken up
in water and ether, the ethereal layer separated, the product washed with
water and dried over sodium sulfate. The solvent is evaporated under reduced
pressure. The residue, which consists of the methyl ester, could not be
obtained in the crystalline state. It is dissolved in 25 ml of acetic acid, heated
under reflux for 15 minutes, the product evaporated to dryness and the
residual oil taken up in ether. A colorless solid separates which is filtered by
suction and recrystallized from methanol. Colorless crystals are obtained (4.7
9); MPk (Kofler block): 226°C. A second crop (1.5 g) is obtained on
concentration of the mother liquor; MPk (Kofler block): 222°C; total quantity
6.2 g, corresponding to a yield of 47%.
(C) Preparation of Dipotassium Salt of [2-Phenyl-2-(2-Amino-5-Chlorophenyl)-
1-Azavinyl] Malonic Acid (4306 CB): 50 g of caustic potash are dissolved in
1,350 ml of 96% ethyl alcohol, and 82 g (0.25 mol) of compound 4347 CB are
then added all at once at a temperature of about 70°C. The solid dissolves
rapidly to form a yellow solution which then loses color while simultaneously
an abundant colorless precipitate appears.
After cooling, the solid is filtered by suction and washed with alcohol at 96°C.
The product is dried at ordinary temperature in a high vacuum. A colorless
solid is obtained (quantitative yield), which is completely soluble in water. The
aqueous solution is strongly alkaline in reaction; when acidified with acetic
acid and heated on a water bath, it yields a precipitate of 7-chloro-5-phenyl-
2-oxo-2,3-dihydro-1H-benzo[f]-1,4-diazepine. | [Brand name]
Tranxene (Ovation). | [Therapeutic Function]
Tranquilizer | [General Description]
Clorazepate dipotassium,7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid dipotassium salt monohydrate(Tranxene), can be considered a prodrug. Inactive itself, itundergoes rapid decarboxylation by the acidity of thestomach to nordazepam (a major active metabolite of diazepam),which has a long half-life and undergoes hepaticconversion to active oxazepam. Despite the polar characterof the drug as administered, because it is quickly convertedin the GI tract to an active nonpolar compound, it has aquick onset, overall long half-life, and shares similar clinicaland pharmacokinetic properties to chlordiazepoxideand diazepam. |
|
|